ScioScientific LLC

04/29/2026

A federal push to increase transparency in prescription drug pricing is facing strong pushback from pharmacy benefit managers and insurers, highlighting the ongoing tension between reform efforts and industry interests. Here's more on this.

Pharma industry middlemen are pushing back on a major drug price transparency proposal.

04/28/2026

A new executive order is accelerating research into psychedelic treatments for PTSD and other mental health conditions, boosting funding, fast-tracking approvals, and signaling a major shift in how these therapies are being explored. Here's more on this.

Trump directed the federal government to rush access to psychedelic treatments and reevaluate their status as controlled substances.

04/27/2026

A new analysis suggests headlines about widespread vaccine skepticism may be overstated, with flawed polling questions masking a more nuanced “middle ground” in public opinion. Read more on this.

Despite some headlines, a new poll does not show that most Americans no longer trust vaccines.

04/26/2026

Maryland’s Prescription Drug Affordability Board has set its first-ever price cap on a diabetes medicine, marking a major step toward state action on drug pricing and affordability in the U.S. Here's more on this.

RFK Jr. focused on President Trump's health care agenda and largely avoided vaccines.

04/25/2026

AI voice chatbots are raising growing concerns in mental health research, with experts warning they may deepen emotional dependency and reinforce harmful thinking in vulnerable users. Here's more on this.

The debate about AI and mental health has so far focused on content. But the way the content is delivered matters, too.

04/24/2026

A key study on the antidepressant Paxil in adolescents has been flagged with an “expression of concern,” reigniting debate over transparency and trust in clinical research. Here's more on this.

When scientific journals publish expressions of concerns, they have an obligation to do so prominently, Ed Silverman writes.

04/23/2026

A breakthrough drug for Hunter syndrome is offering new hope, but age-based approval limits mean many adult patients are still left without access, highlighting ongoing gaps in rare disease treatment and policy. Here's more on this.

Rare disease clinical trials, policy discussions, and advocacy initiatives often leave adults behind.

04/22/2026

The FDA is urging drugmakers to report missing clinical trial results after finding that nearly 30% of required studies lacked data. The move highlights ongoing transparency gaps and raises questions about how incomplete reporting may impact patient safety and trust in medical research. Here's more on this.

FDA officials said an internal analysis found results were not submitted for nearly 30% of studies “highly likely” to fall under mandatory reporting requirements.

04/21/2026

A new analysis suggests a softer stance on Medicare Advantage underwriting could benefit insurers, but what does it mean for patients, costs, and oversight? Is this a win for access or a risk for accountability?

President Trump vowed to take on health insurers, but his policies tell a different story.

04/20/2026

Erectile dysfunction may be more than a sexual health issue. It can be an early warning sign linked to cardiovascular disease and even increased dementia risk, highlighting the importance of early screening and heart health checks. Read more on this. ’sHealth

Erectile dysfunction is more than a sexual issue.

04/19/2026

After a legal setback, U.S. health officials have revised the CDC vaccine advisory panel’s charter broadening membership and emphasizing potential vaccine risks in a move critics say could reshape vaccine policy and public trust. Here's more on this.

04/18/2026

A new report shows wide disparities in U.S. health care spending, with metros like Charleston, West Virginia, and New York among the highest, highlighting how costs vary dramatically by location, not just access or quality. Here's more on this.

There's not a consistent theme among the 10 highest and lowest spending metros, which highlights the “irrationality” of U.S. health care spending, experts say.